NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $23.99 +0.37 (+1.57%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$23.27▼$24.1450-Day Range$19.86▼$25.3052-Week Range$18.94▼$48.56Volume386,790 shsAverage Volume780,935 shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/APrice Target$42.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AtriCure alerts: Email Address AtriCure MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside76.9% Upside$42.44 Price TargetShort InterestHealthy6.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.85Based on 11 Articles This WeekInsider TradingAcquiring Shares$111,250 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.77) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.00 out of 5 starsMedical Sector180th out of 924 stocksSurgical & Medical Instruments Industry26th out of 97 stocks 4.5 Analyst's Opinion Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtriCure has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AtriCure's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.54% of the outstanding shares of AtriCure have been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AtriCure has recently decreased by 14.33%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATRC. Previous Next 3.3 News and Social Media Coverage News SentimentAtriCure has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for AtriCure this week, compared to 4 articles on an average week.Search Interest3 people have searched for ATRC on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have bought 32.06% more of their company's stock than they have sold. Specifically, they have bought $111,250.00 in company stock and sold $84,245.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($0.77) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -29.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -29.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AtriCure's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About AtriCure Stock (NASDAQ:ATRC)AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Read More ATRC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRC Stock News HeadlinesAugust 20 at 5:18 AM | insidertrades.comAtriCure, Inc. (NASDAQ:ATRC) Director Maggie Yuen Sells 3,500 SharesAugust 19 at 7:05 PM | bizjournals.comAtriCure leadership explains $45M investment in Greater Cincinnati HQAugust 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.August 19 at 9:24 AM | americanbankingnews.comAtriCure, Inc. (NASDAQ:ATRC) Director Sells $84,245.00 in StockAugust 19 at 5:18 AM | americanbankingnews.comAtriCure, Inc. (NASDAQ:ATRC) Short Interest UpdateAugust 15, 2024 | finance.yahoo.comTop 3 Undervalued Small Caps With Insider Buys To Watch In United States August 2024August 15, 2024 | markets.businessinsider.comAtricure’s Market Strength and Innovation Justify Buy RatingAugust 15, 2024 | americanbankingnews.comAnalysts Set AtriCure, Inc. (NASDAQ:ATRC) Price Target at $42.44August 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.August 12, 2024 | finance.yahoo.comATRC Aug 2024 17.500 put (ATRC240816P00017500)August 2, 2024 | finance.yahoo.comUS$39.89: That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After Its Latest ResultsAugust 1, 2024 | markets.businessinsider.comAtricure’s Stable Financials and Strategic Growth Outlook Justify Buy RatingJuly 31, 2024 | seekingalpha.comAtriCure, Inc. (ATRC) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | markets.businessinsider.comAtriCure’s Growth Prospects and Buy Rating Despite Short-Term ChallengesJuly 31, 2024 | msn.comAtriCure, Inc. (NASDAQ:ATRC) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | stockhouse.comAtriCure Reports Second Quarter 2024 Financial ResultsJuly 30, 2024 | investorplace.comATRC Stock Earnings: AtriCure Meets EPS, Beats Revenue for Q2 2024July 30, 2024 | finance.yahoo.comAtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth ConferenceSee More Headlines Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/30/2024Today8/21/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATRC CUSIP04963C20 CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,050Year Founded2000Price Target and Rating Average Stock Price Target$42.44 High Stock Price Target$60.00 Low Stock Price Target$26.00 Potential Upside/Downside+76.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,440,000.00 Net Margins-9.33% Pretax Margin-9.13% Return on Equity-8.39% Return on Assets-6.45% Debt Debt-to-Equity Ratio0.16 Current Ratio4.13 Quick Ratio2.83 Sales & Book Value Annual Sales$429.95 million Price / Sales2.66 Cash FlowN/A Price / Cash FlowN/A Book Value$9.49 per share Price / Book2.53Miscellaneous Outstanding Shares47,588,000Free Float46,065,000Market Cap$1.14 billion OptionableOptionable Beta1.44 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Michael H. Carrel (Age 53)CEO, President & Director Comp: $2.01MMs. Angela L. Wirick CPA (Age 46)Chief Financial Officer Comp: $841.54kMr. Douglas J. Seith (Age 58)Chief Operating Officer Comp: $1.2MMr. Salvatore Privitera J.D. (Age 57)Chief Technical Officer Comp: $758.8kMr. Karl S. Dahlquist CCEP (Age 53)J.D., Chief Legal Officer Comp: $762.39kDr. Vinayak Doraiswamy Ph.D. (Age 52)Chief Scientific Officer Comp: $777.66kValerie Storch-WillhausVice President of Corporate Marketing & CommunicationsMr. Justin J. Noznesky (Age 46)Chief Marketing & Strategy Officer Comp: $644.73kMs. Deborah Yount (Age 58)Chief Human Resources Officer Comp: $498.36kMore ExecutivesKey CompetitorsCardiovascular SystemsNASDAQ:CSIIAtrionNASDAQ:ATRIPulmonxNASDAQ:LUNGInovio PharmaceuticalsNASDAQ:INONuVasiveNASDAQ:NUVAView All CompetitorsInsiders & InstitutionsTruist Financial CorpBought 1,842 shares on 8/21/2024Ownership: 0.032%Algert Global LLCSold 9,918 shares on 8/16/2024Ownership: 0.191%AQR Capital Management LLCBought 16,251 shares on 8/15/2024Ownership: 0.123%The Manufacturers Life Insurance Company Bought 1,429 shares on 8/15/2024Ownership: 0.052%Deerfield Management Company L.P. Series CSold 3,672 shares on 8/15/2024Ownership: 0.036%View All Insider TransactionsView All Institutional Transactions ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $35.69 at the start of the year. Since then, ATRC shares have decreased by 32.8% and is now trading at $23.99. View the best growth stocks for 2024 here. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) announced its quarterly earnings results on Tuesday, July, 30th. The medical device company reported ($0.17) EPS for the quarter, meeting the consensus estimate of ($0.17). The business's revenue was up 15.2% compared to the same quarter last year. What is Michael Carrel's approval rating as AtriCure's CEO? 38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend. Does AtriCure have any subsidiaries? AtriCure subsidiaries include these companies: SentreHEART. Who are AtriCure's major shareholders? Top institutional shareholders of AtriCure include First Light Asset Management LLC (4.13%), Hood River Capital Management LLC (3.73%), Millennium Management LLC (2.00%) and Fiera Capital Corp (1.93%). Insiders that own company stock include Salvatore Privitera, Justin J Noznesky, Karl S Dahlquist, Vinayak Doraiswamy, Tonya Austin, Karen Prange, Maggie Yuen, Angela L Wirick, Douglas J Seith and Mark A Collar. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT) and Neurocrine Biosciences (NBIX). This page (NASDAQ:ATRC) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATRC Stock Alerts